Table 2.
Clinical and Molecular Features of CRC According to Microsatellite Status n (%)
| Factors(n) | MSI (n=22) | MSS (n=162) | χ2 | df | P value |
|---|---|---|---|---|---|
| Sex | 1.783 | 1 | 0.182 | ||
| Male(101) | 15 (14.9) | 86 (85.1) | |||
| Female(83) | 7 (8.4) | 76 (91.6) | |||
| Age | 0.701 | 1 | 0.402 | ||
| <60 (85) | 12 (14.1) | 73 (85.9) | |||
| ≥60 (99) | 10 (10.1) | 89 (89.9) | |||
| Tumor location | 11.659 | 2 | 0.003** | ||
| Proximal colon(47) | 12 (25.5) | 35 (74.5) | |||
| Distal colon(62) | 6 (9.7) | 56 (90.3) | |||
| Rectum(75) | 4 (5.3) | 71 (94.7) | |||
| TNM Stages | 8.633 | 3 | 0.035* | ||
| Stage I (21) | 0 (0) | 21 (100) | |||
| Stage II(95) | 11 (11.6) | 84 (88.4) | |||
| Stage III (26) | 7 (26.9) | 19 (73.1) | |||
| Stage IV(42) | 4 (9.5) | 38 (90.5) | |||
| HER-2 | 6.248 | 2 | 0.044* | ||
| Negative (68) | 14 (20.6) | 54 (79.4) | |||
| Positive +(67) | 6 (9.0) | 61 (91.0) | |||
| Positive ++(36) | 2 (5.6) | 34 (94.4) | |||
| CD31 | 14.126 | 1 | <0.01** | ||
| Negative (25) | 9 (36.0) | 16 (64.0) | |||
| Positive (147) | 13 (8.8) | 134 (91.2) | |||
| D2-40 | 14.126 | 1 | <0.01** | ||
| Negative (25) | 9 (36.0) | 16 (64.0) | |||
| Positive (147) | 13 (8.8) | 134 (91.2) | |||
| Syn | 0.297 | 1 | 0.586 | ||
| Negative(155) | 18 (11.6) | 137 (88.4) | |||
| Positive (26) | 4 (15.4) | 22 (84.6) | |||
| CgA | 1.778 | 1 | 0.182 | ||
| Negative(159) | 22 (13.0) | 147 (87.0) | |||
| Positive (22) | 0 (0) | 22 (100) |
Note: *p <0.05 and **p<0.01 were considered to be statistically significant.
Abbreviations: df, degree of freedom; CRC, colorectal cancer; HER-2, human epidermal growth factor receptor-2; Syn, synaptophysin; CgA, chromogranin A; MSS, microsatellite stability; MSI, microsatellite instability.